A Clinical Trial to Evaluate the Safety and Efficacy of an Implantable Wireless Brain-Computer Interface（BCI）System NEO in Patients With Tetraplegia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-20

Study Completion Date

2026-05-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety and efficacy of a Minimally Invasive Wireless Implantable Brain-Computer Interface (BCI) System NEO in patients with tetraplegia and to provide a basis for product registration.

Through brain-computer interface alternative technology, patients can control the external equipment with brain signals to improve the patient's quality of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial to Evaluate the Safety and Efficacy of an Implantable Neural Acquisitor & Stimulator System in Patients With Motor Disability

NCT05920174

Tetraplegia

RECRUITING NA

Microelectrode Brain-Machine Interface for Individuals With Tetraplegia

NCT01364480

Tetraplegia Spinal Cord Injury

TERMINATED NA

BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

NCT00912041

Tetraplegia Spinal Cord Injuries Amyotrophic Lateral Sclerosis +3 more

RECRUITING NA

Nerve Transfer to Improve Function in High Level Tetraplegia

NCT06288763

Cervical Spinal Cord Injury Tetraplegia

RECRUITING

A User-friendly, Non-invasive Neuro-orthosis That Restores Volitionally Controlled Grasp Functions for SCI Survivors With Tetraplegia

NCT06087445

Cervical Spinal Cord Injury

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tetraplegia Spinal Cord Injuries (SCI)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

a Minimally Invasive Wireless Implantable Brain-Computer Interface (BCI) System NEO

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment group

a Minimally Invasive Wireless Implantable Brain-Computer Interface (BCI) System NEO

Group Type EXPERIMENTAL

NEO

Intervention Type DEVICE

a Minimally Invasive Wireless Implantable Brain-Computer Interface (BCI) System NEO

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NEO

a Minimally Invasive Wireless Implantable Brain-Computer Interface (BCI) System NEO

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age between 18 and 65 years old, no restriction on gender.
2. Tetraplegia caused by cervical spinal cord injury.
3. Score of ≤1 on either the ball grasp or water pouring tasks of the ARAT (Action Research Arm Test).
4. Muscle strength of finger flexors \< grade 3 according to ISNCSCI (International Standards for Neurological Classification of Spinal Cord Injury).
5. Score of ≥2 for "hand to mouth" on ARAT; scores of ≥1 for both "hand to top of head" and "hand to behind the head."
6. Neurological assessment indicates normal function of the motor-related cortex, with no significant structural lesions or functional disorders identified.
7. Diagnosis confirmed for at least 12 months, with a stable condition for at least 6 months following standard treatment.
8. Normal cognitive function, good compliance, and voluntarily agrees to participate in the clinical trial.

Exclusion Criteria

1. Without the consent of the patient or the patient's legal guardian.
2. Presence of syringomyelia, severe neuropathic pain, or severe spasticity that limits the participant's ability to engage in training.
3. Requires ventilator support.
4. Baclofen dosage \>30 mg/day.
5. Received botulinum toxin injections in the upper limb, neck, or hand within 6 months prior to enrollment, or received stem cell therapy within 1 year.
6. High risk of surgical complications, such as active systemic infection, coagulation disorders (e.g., receiving anticoagulant therapy), or platelet count below 50,000.
7. Patients who have already been implanted with medical devices that deliver electrical energy to the central nervous system.
8. Any unstable or significant medical condition that may interfere with study procedures or confound the evaluation of study endpoints, such as depression, mood disorders, or other cognitive impairments.
9. Diagnosed with severe, unstable, and uncontrolled complex regional pain syndrome.
10. Autoimmune-mediated spinal cord dysfunction/injury.
11. History of other neurological disorders, such as stroke, multiple sclerosis, traumatic brain injury, or drug-resistant epilepsy.
12. Peripheral neuropathies (e.g. diabetic polyneuropathy, compressive neuropathies).
13. In the investigator's opinion, the study is unsafe or inappropriate for the participant, or the participant is unlikely to comply with the study follow-up schedule.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No